Nuclear pharmacy

Last updated
Pharmaceutical drug which emits radiation, used as a diagnostic or therapeutic agent Radiopharmaceutical.jpg
Pharmaceutical drug which emits radiation, used as a diagnostic or therapeutic agent

Nuclear pharmacy, also known as radiopharmacy, involves preparation of radioactive materials for patient administration that will be used to diagnose and treat specific diseases in nuclear medicine. It generally involves the practice of combining a radionuclide tracer with a pharmaceutical component that determines the biological localization in the patient. [1] [2] Radiopharmaceuticals are generally not designed to have a therapeutic effect themselves, but there is a risk to staff from radiation exposure and to patients from possible contamination in production. [3] Due to these intersecting risks, nuclear pharmacy is a heavily regulated field. [4] [5] The majority of diagnostic nuclear medicine investigations are performed using technetium-99m. [6]

Contents

History

The concept of nuclear pharmacy was first described in 1960 by Captain William H. Briner while at the National Institutes of Health (NIH) in Bethesda, Maryland. Along with Mr. Briner, John E. Christian, who was a professor in the School of Pharmacy at Purdue University, had written articles and contributed in other ways to set the stage of nuclear pharmacy. William Briner started the NIH Radiopharmacy in 1958. [7] [8] John Christian and William Briner were both active on key national committees responsible for the development, regulation and utilization of radiopharmaceuticals. A technetium-99m generator was commercially available, followed by the availability of a number of Tc-99m based radiopharmaceuticals.

In the United States nuclear pharmacy was the first pharmacy specialty established in 1978 by the Board of Pharmacy Specialties. [9]

Various models of production exist internationally. Institutional nuclear pharmacy is typically operated through large medical centers or hospitals while commercial centralized nuclear pharmacies provide their services to subscriber hospitals. They prepare and dispense radiopharmaceuticals as unit doses that are then delivered to the subscriber hospital by nuclear pharmacy personnel.

Operation

A few basic steps are typically involved in technetium based preparations. First the active technetium is obtained from a radionuclide generator on site, which is then added to a non-radioactive kit containing the pharmaceutical component. Further steps may be required depending on the materials in question to ensure full binding of the two components. These procedures are usually carried out in a clean room or isolator to provide radiation shielding and sterile conditions. [10] [11]

For Positron Emission Tomography (PET), Fludeoxyglucose (18F) is the most common radiopharmaceutical, with the radioactive component usually obtained from a cyclotron. [11] The short half life of Fluorine-18 and many other PET isotopes necessitates rapid production. PET radiopharmaceuticals are now often produced by automated computer controlled systems to reduce complexity and radiation doses to staff. [12]

Training and regulation

Radiopharmacy is a heavily regulated field, as it combines several practices and fields which may come under the purview of multiple regulators and legislation. These include occupational exposure of staff to ionising radiation, preparation of medicines, patient exposure to ionising radiation, transport of radioactive materials, and environmental exposure to ionising radiation. [13] Different regulations may cover the various stages involved in radiopharmacies, ranging from production of "cold" (non-radioactive) kits, to the marketing and distribution of final products. [14]

Staff working in nuclear pharmacies require extensive training on aspects of good manufacturing practice, radiation safety concerns and aseptic dispensing. In the United States an authorised nuclear pharmacist must be a fully qualified pharmacist with evidence of additional training and qualification in nuclear pharmacy practice. [15] Several European Union directives cover radiopharmaceuticals as a special group of medicines, reflecting the wide range of types of producers and staff groups that may be involved. [16] In the UK qualified pharmacists may be involved along with clinical scientists or technologists, with relevant training. [17]

See also

Related Research Articles

A synthetic radioisotope is a radionuclide that is not found in nature: no natural process or mechanism exists which produces it, or it is so unstable that it decays away in a very short period of time. Examples include technetium-95 and promethium-146. Many of these are found in, and harvested from, spent nuclear fuel assemblies. Some must be manufactured in particle accelerators.

Medical physics deals with the application of the concepts and methods of physics to the prevention, diagnosis and treatment of human diseases with a specific goal of improving human health and well-being. Since 2008, medical physics has been included as a health profession according to International Standard Classification of Occupation of the International Labour Organization.

Radionuclide therapy uses radioactive substances called radiopharmaceuticals to treat medical conditions, particularly cancer. These are introduced into the body by various means and localise to specific locations, organs or tissues depending on their properties and administration routes. This includes anything from a simple compound such as sodium iodide that locates to the thyroid via trapping the iodide ion, to complex biopharmaceuticals such as recombinant antibodies which are attached to radionuclides and seek out specific antigens on cell surfaces.

<span class="mw-page-title-main">Nuclear medicine</span> Medical specialty

Nuclear medicine or nucleology is a medical specialty involving the application of radioactive substances in the diagnosis and treatment of disease. Nuclear imaging, in a sense, is "radiology done inside out" because it records radiation emitted from within the body rather than radiation that is transmitted through the body from external sources like X-ray generators. In addition, nuclear medicine scans differ from radiology, as the emphasis is not on imaging anatomy, but on the function. For such reason, it is called a physiological imaging modality. Single photon emission computed tomography (SPECT) and positron emission tomography (PET) scans are the two most common imaging modalities in nuclear medicine.

<span class="mw-page-title-main">Radiopharmacology</span> Pharmacologic study of radiated medical compounds

Radiopharmacology is radiochemistry applied to medicine and thus the pharmacology of radiopharmaceuticals. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases. Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide. In the book Technetium a total of 31 different radiopharmaceuticals based on Tc-99m are listed for imaging and functional studies of the brain, myocardium, thyroid, lungs, liver, gallbladder, kidneys, skeleton, blood and tumors.

<span class="mw-page-title-main">Radionuclide angiography</span> Nuclear medicine imaging the ventricles of the heart

Radionuclide angiography is an area of nuclear medicine which specialises in imaging to show the functionality of the right and left ventricles of the heart, thus allowing informed diagnostic intervention in heart failure. It involves use of a radiopharmaceutical, injected into a patient, and a gamma camera for acquisition. A MUGA scan involves an acquisition triggered (gated) at different points of the cardiac cycle. MUGA scanning is also called equilibrium radionuclide angiocardiography, radionuclide ventriculography (RNVG), or gated blood pool imaging, as well as SYMA scanning.

<span class="mw-page-title-main">Technetium-99m generator</span> A device used to extract the short-lived radioactive isotope Tc-99m from a longer-lived Mo-99 source

A technetium-99m generator, or colloquially a technetium cow or moly cow, is a device used to extract the metastable isotope 99mTc of technetium from a decaying sample of molybdenum-99. 99Mo has a half-life of 66 hours and can be easily transported over long distances to hospitals where its decay product technetium-99m is extracted and used for a variety of nuclear medicine diagnostic procedures, where its short half-life is very useful.

<span class="mw-page-title-main">Pertechnetate</span> Chemical compound or ion

The pertechnetate ion is an oxyanion with the chemical formula TcO−
4. It is often used as a convenient water-soluble source of isotopes of the radioactive element technetium (Tc). In particular it is used to carry the 99mTc isotope which is commonly used in nuclear medicine in several nuclear scanning procedures.

<span class="mw-page-title-main">Ventilation/perfusion scan</span> Medical imaging to evaluate circulation of air and blood in the lungs

A ventilation/perfusion lung scan, also called a V/Q lung scan, or ventilation/perfusion scintigraphy, is a type of medical imaging using scintigraphy and medical isotopes to evaluate the circulation of air and blood within a patient's lungs, in order to determine the ventilation/perfusion ratio. The ventilation part of the test looks at the ability of air to reach all parts of the lungs, while the perfusion part evaluates how well blood circulates within the lungs. As Q in physiology is the letter used to describe bloodflow the term V/Q scan emerged.

<span class="mw-page-title-main">Technetium-99m</span> Metastable nuclear isomer of technetium-99

Technetium-99m (99mTc) is a metastable nuclear isomer of technetium-99, symbolized as 99mTc, that is used in tens of millions of medical diagnostic procedures annually, making it the most commonly used medical radioisotope in the world.

<span class="mw-page-title-main">Myocardial perfusion imaging</span> Nuclear medicine imaging method

Myocardial perfusion imaging or scanning is a nuclear medicine procedure that illustrates the function of the heart muscle (myocardium).

Technetium (<sup>99m</sup>Tc) medronic acid Chemical compound

Technetium (99mTc) medronic acid is a pharmaceutical product used in nuclear medicine to localize bone metastases as well as other diseases that can alter the natural turn-over in the bone by bone scintigraphy.

Technetium 99mTc albumin aggregated (99mTc-MAA) is an injectable radiopharmaceutical used in nuclear medicine. It consists of a sterile aqueous suspension of Technetium-99m (99mTc) labeled to human albumin aggregate particles. It is commonly used for lung perfusion scanning. It is also less commonly used to visualise a peritoneovenous shunt and for isotope venography.

<span class="mw-page-title-main">Octreotide scan</span>

An octreotide scan is a type of SPECT scintigraphy used to find carcinoid, pancreatic neuroendocrine tumors, and to localize sarcoidosis. It is also called somatostatin receptor scintigraphy (SRS). Octreotide, a drug similar to somatostatin, is radiolabeled with indium-111, and is injected into a vein and travels through the bloodstream. The radioactive octreotide attaches to tumor cells that have receptors for somatostatin. A gamma camera detects the radioactive octreotide, and makes pictures showing where the tumor cells are in the body, typically by a SPECT technique. A technetium-99m based radiopharmaceutical kit is also available.

<span class="mw-page-title-main">Radiation monitoring</span> Measurement of radiation doses or contamination

Radiation monitoring involves the measurement of radiation dose or radionuclide contamination for reasons related to the assessment or control of exposure to radiation or radioactive substances, and the interpretation of the results.

<span class="mw-page-title-main">Radiopharmaceutical</span> Pharmaceutical drug which emits radiation, used as a diagnostic or therapeutic agent

Radiopharmaceuticals, or medicinal radiocompounds, are a group of pharmaceutical drugs containing radioactive isotopes. Radiopharmaceuticals can be used as diagnostic and therapeutic agents. Radiopharmaceuticals emit radiation themselves, which is different from contrast media which absorb or alter external electromagnetism or ultrasound. Radiopharmacology is the branch of pharmacology that specializes in these agents.

Sandip Basu is an Indian physician of Nuclear Medicine and the Head, Nuclear Medicine Academic Program at the Radiation Medicine Centre. He is also the Dean-Academic (Health-Sciences), BARC at Homi Bhabha National Institute and is known for his services and research in Nuclear Medicine, particularly on Positron emission tomography diagnostics and Targeted Radionuclide Therapy in Cancer. The Council of Scientific and Industrial Research, the apex agency of the Government of India for scientific research, awarded him the Shanti Swarup Bhatnagar Prize for Science and Technology, one of the highest Indian science awards for his contributions to Nuclear Medicine in 2012.

<span class="mw-page-title-main">Peptide receptor radionuclide therapy</span> Type of radiotherapy

Peptide receptor radionuclide therapy (PRRT) is a type of radionuclide therapy, using a radiopharmaceutical that targets peptide receptors to deliver localised treatment, typically for neuroendocrine tumours (NETs).

A radionuclide generator is a device which provides a local supply of a short-lived radioactive substance from the decay of a longer-lived parent radionuclide. They are commonly used in nuclear medicine to supply a radiopharmacy. The generator provides a way to separate the desired product from the parent, typically in a process that can be repeated several times over the life of the parent.

Organotechnetium chemistry is the science of describing the physical properties, synthesis, and reactions of organotechnetium compounds, which are organometallic compounds containing carbon-to-technetium chemical bonds. The most common organotechnetium compounds are coordination complexes used as radiopharmaceutical imaging agents.

References

  1. ↑ Christian, John E. (June 1948). "The applications of radioactive tracer techniques to pharmacy and pharmaceutical research". Journal of the American Pharmaceutical Association (Scientific Ed.). 37 (6): 250–253. doi:10.1002/jps.3030370614. PMID   18865179.
  2. ↑ Vallabhajosula, Shankar; Owunwanne, Azu (2006). "Pathophysiology and Mechanisms of Radiopharmaceutical Localization". In Elgazzar, Abdelhamid H. (ed.). The pathophysiologic basis of nuclear medicine (2nd ed.). Berlin: Springer. pp. 29–49. ISBN   978-3-540-47953-6.
  3. ↑ IAEA (2008). Operational guidance on hospital radiopharmacy: a safe and effective approach. Vienna: International Atomic Energy Agency. ISBN   978-92-0-106708-1.
  4. ↑ Gill, J R; Turner, J L (1995). "Regulatory Requirements for the Dispensing and Supply of Radiopharmaceuticals". In Sampson, Charles B. (ed.). Textbook of radiopharmacy: theory and practice (2nd ed.). Luxembourg: Gordon and Breach. p. 181. ISBN   9782881249730.
  5. ↑ Elsinga, Philip; Todde, Sergio; Penuelas, Ivan; Meyer, Geerd; Farstad, Brit; Faivre-Chauvet, Alain; Mikolajczak, Renata; Westera, Gerrit; Gmeiner-Stopar, Tanja; Decristoforo, Clemens (20 March 2010). "Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals" (PDF). European Journal of Nuclear Medicine and Molecular Imaging. 37 (5): 1049–1062. doi:10.1007/s00259-010-1407-3. PMC   2854359 . PMID   20306035.
  6. ↑ IAEA (2009). Technetium-99m radiopharmaceuticals: status and trends. Vienna: International Atomic Energy Agency. ISBN   978-92-0-103509-7.
  7. ↑ Shaw, SM; Ice, RD (March 2000). "Nuclear pharmacy, Part I: Emergence of the specialty of nuclear pharmacy" (PDF). Journal of Nuclear Medicine Technology. 28 (1): 8–11, quiz 20. PMID   10763775.
  8. ↑ Troy, David B. (2005). Remington: The science and practice of pharmacy (21st ed.). Philadelphia, PA: Lippincott, Williams & Wilkins. p. 1915. ISBN   9780781746731.
  9. ↑ "Board of Pharmacy Specialties Celebrates 40th Anniversary". BPS. Retrieved 5 January 2017.
  10. ↑ "Radiopharmaceuticals". The International Pharmacopoeia (6th ed.). WHO. 2016.
  11. 1 2 IAEA (2007). "Annex II Radiopharmaceuticals: Production and Availability" (PDF). Nuclear Technology Review. Vienna: International Atomic Energy Agency. p. 60.
  12. ↑ Jacobsen, Mark S; Steichen, Raymond A; Peller, Patrick J (2012). "PET Radiochemistry and Radiopharmacy". In Peller, Patrick; Subramaniam, Rathan; Guermazi, Ali (eds.). PET/CT and PET-MRI in Oncology : a practical guide. Berlin: Springer. pp. 19–30. doi:10.1007/174_2012_703. ISBN   978-3-642-01138-2.
  13. ↑ Ballinger, James R (2016). "Hospital Radiopharmacy in the UK". In McCready, R; Gnanasegaran, G; Bomanji, J (eds.). A history of radionuclide studies in the UK. Springer. pp. 129–134. doi: 10.1007/978-3-319-28624-2_17 . ISBN   978-3-319-28623-5. PMID   29787092.
  14. ↑ IAEA (2008). Operational guidance on hospital radiopharmacy: a safe and effective approach. Vienna: International Atomic Energy Agency. ISBN   978-92-0-106708-1.
  15. ↑ "10 CFR 35.55 Training for an authorized nuclear pharmacist". NRC. 2015. Retrieved 5 January 2017.
  16. ↑ Verbruggen, Alfons; Coenen, Heinz H.; Deverre, Jean-Robert; Guilloteau, Denis; Langstrom, Bengt; Salvadori, Piero A.; Halldin, Christer (9 August 2008). "Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU" (PDF). European Journal of Nuclear Medicine and Molecular Imaging. 35 (11): 2144–2151. doi:10.1007/s00259-008-0853-7. PMID   18690437. S2CID   12062317.
  17. ↑ "What does a Radiopharmacist do?". BNMS. Retrieved 5 January 2017.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.